Bacterial membrane vesicles as promising vaccine candidates

Eur J Pharm Biopharm. 2019 Dec:145:1-6. doi: 10.1016/j.ejpb.2019.09.021. Epub 2019 Sep 24.

Abstract

Both Gram-positive and Gram-negative bacteria can release nano-sized lipid bilayered structures, known as membrane vesicles (MVs). These MVs play an important role in bacterial survival by orchestrating interactions between bacteria and between bacteria and host. The major constituents of MVs are proteins, lipids and nucleic acids. Due to the immunogenicity of the membrane lipids and/or proteins of the MVs, in combination with adjuvant danger signals and the repeating patterns on the nanosized surface, MVs can effectively stimulate the innate and adaptive immune system. Since they are non-replicating, they are safer than attenuated vaccines. In addition, by genetic engineering of the donor cells, further improvements to their safety profile, immunogenicity and yield can be achieved. To date, one MV-based vaccine against Neisseria meningitidis (N. meningitidis) serogroup B was approved. Other (engineered) MVs in the pipeline study are mostly in the preclinical phase.

Publication types

  • Review

MeSH terms

  • Adaptive Immunity / immunology
  • Adjuvants, Immunologic
  • Animals
  • Antibody Formation / immunology
  • Bacteria / immunology*
  • Bacterial Proteins / immunology
  • Humans
  • Lipid Bilayers / immunology*
  • Membrane Lipids / immunology*
  • Membranes / immunology*
  • Vaccines / immunology*

Substances

  • Adjuvants, Immunologic
  • Bacterial Proteins
  • Lipid Bilayers
  • Membrane Lipids
  • Vaccines